Form 4: Telomir Pharmaceuticals Director Acquires Incentive Stock Options

Director Edward Clouston MacPherson acquired 25,000 incentive stock options in Telomir Pharmaceuticals on August 27, 2024.

Summary

• On August 27, 2024, Edward Clouston MacPherson, a director of Telomir Pharmaceuticals, acquired 25,000 incentive stock options.
• The exercise price of these options is $5.02, which was the closing price of Telomir's common stock on August 26, 2024.
• The options were granted under the company's 2023 Omnibus Incentive Plan.
• 50% of the options vested immediately, and the remaining 50% will vest on February 26, 2025.
• The options expire on August 27, 2034.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral. The grant itself can be seen as a positive sign of aligning management interests with shareholders, but it's not a major event.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders. The vesting schedule is typical for such grants.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the pharmaceutical and biotechnology sectors.
• The vesting schedule of 50% immediately and 50% after six months is fairly standard.
• Comparable companies in the biotechnology space, such as Amylyx Pharmaceuticals or BioVie, often use similar incentive plans to attract and retain talent.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment as it aligns the director's interests with those of the shareholders.

Key Dates